Read the full interview:
Pulmonary fibrosis is a chronic and usually fatal disease. The project will investigate the anti-fibrotic effects of TOP-V122.
Read moreWe are proud to be recognized as one of Switzerland's most promising scale-ups in 2022.
Read moreTOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.
Read more